{"filing":{"accession_number":"0001185185-26-003794","cik":"0001771885","ticker":"QNTM","company_name":"Quantum Biopharma Ltd.","form":"6-K","filing_date":"2026-09-01","report_date":"2026-09-01","primary_document":"qntm6k090126.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1771885/000118518526003794/qntm6k090126.htm"},"events":[{"id":31114,"run_id":28537,"accession_number":"0001185185-26-003794","anchor_item_number":"EX-99.1","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"summary":"Quantum BioPharma announces a voluntary delisting of its Class B shares from the Canadian Securities Exchange (CSE), effective September 4, 2026. While characterized as voluntary and intended to consolidate trading on Nasdaq, this is a material change in listing status that affects shareholder trading options, liquidity, and market access. The disclosure explicitly identifies risks including reduced trading volume, liquidity, and analyst coverage, as well as potential impacts on resale exemptions and the company's ability to complete private placements—all factors a reasonable investor would consider when assessing the registrant's capital-raising ability and share liquidity.","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-09-01","form":"6-K","submitted_at":null,"items":[{"id":33915,"accession_number":"0001185185-26-003794","item_number":"EX-99.1","item_title":"qntmex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Quantum BioPharma announces a voluntary delisting of its Class B shares from the Canadian Securities Exchange (CSE), effective September 4, 2026. While characterized as voluntary and intended to consolidate trading on Nasdaq, this is a material change in listing status that affects shareholder trading options, liquidity, and market access. The disclosure explicitly identifies risks including reduced trading volume, liquidity, and analyst coverage, as well as potential impacts on resale exemptions and the company's ability to complete private placements—all factors a reasonable investor would consider when assessing the registrant's capital-raising ability and share liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:06:14.760890+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":33915,"accession_number":"0001185185-26-003794","item_number":"EX-99.1","item_title":"qntmex99-1.htm","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.95,"reasoning":"Quantum BioPharma announces a voluntary delisting of its Class B shares from the Canadian Securities Exchange (CSE), effective September 4, 2026. While characterized as voluntary and intended to consolidate trading on Nasdaq, this is a material change in listing status that affects shareholder trading options, liquidity, and market access. The disclosure explicitly identifies risks including reduced trading volume, liquidity, and analyst coverage, as well as potential impacts on resale exemptions and the company's ability to complete private placements—all factors a reasonable investor would consider when assessing the registrant's capital-raising ability and share liquidity.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-02T10:06:14.760890+00:00","company_name":"Quantum Biopharma Ltd.","ticker":"QNTM","filing_date":"2026-09-01"}]}